• In a trial of kidney transplant recipients with late antibody-mediated rejection, treatment with bortezomib, a type of proteasome inhibitor, failed to improve the function of transplanted kidneys and prevent immunologic tissue injury.
• Bortezomib treatment was also linked with gastrointestinal and hematologic toxicity.